PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

Archive ouverte

Casasnovas, Rene-Olivier | Bouabdallah, Reda | Brice, Pauline | Lazarovici, Julien | Ghesquieres, Hervé | Stamatoullas, Aspasia | Dupuis, Jehan | Gac, Anne-Claire | Gastinne, Thomas | Joly, Bertrand | Bouabdallah, Krimo | Nicolas-Virelizier, Emmanuelle | Feugier, Pierre | Morschhauser, Franck | Delarue, Richard | Farhat, Hassan | Quittet, Philippe | Berriolo-Riedinger, Alina | Tempescul, Adrian | Edeline, Véronique | Maisonneuve, Hervé | Fornecker, Luc-Matthieu | Lamy, Thierry | Delmer, Alain | Dartigues, Peggy | Martin, Laurent | Andre, Marc | Mounier, Nicolas | Traverse-Glehen, Alexandra | Meignan, Michel

Edité par CCSD ; Elsevier -

International audience. Increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPescalated) improves progression-free survival in patients with advanced Hodgkin lymphoma compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), but is associated with increased risks of haematological toxicity, secondary myelodysplasia or leukaemia, and infertility. We investigated whether PET monitoring during treatment could allow dose de-escalation by switching regimen (BEACOPPescalated to ABVD) in early responders without loss of disease control compared with standard treatment without PET monitoring. . Programme Hospitalier de Recherche Clinique.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion